Akebia Therapeutics is a discovery and development company focused on the treatment of chronic anemia. Akebia's lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in Phase 2 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimulate endogenous EPO production.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/04/13 | $41,000,000 | Series C |
AgeChem Venture Fund Kearny Venture Partners Novartis Venture Funds Novo A/S Satter Investment Management Triathlon Medical Ventures Venture Investors | undisclosed |
